Vaxon Biotech   Report issue

For profit Phase 1 Phase 2
Founded: Paris France (2004)
Status: Defunct (2018)

Organization Overview

First Clinical Trial
2012
NCT01935154
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

vx-001 (1 trial)

Drugs in Phase 1 Trials (1)

vx-006 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2